478055-47-9

Upstream product

• 211247-61-9 1-(4-nitrophenyl)-4-(piperidin-1-yl)piperidine 
• 4897-50-1 4-piperidinopiperidin 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1021361-58-9 N-(4-[1,4']bipiperidinyl-1'-ylphenyl)-4-(2-phenoxyphenylsulfamoyl)benzamide 
• 1021361-30-7 N-(4-[1,4']bipiperidinyl-1'-ylphenyl)-4-[2-(2,4-dichlorophenoxy)phenylsulfamoyl]benzamide 
• 1374416-61-1 C₃₃H₃₈Cl₂N₄O₃S 
• 1374416-58-6 C₃₃H₃₈Cl₂N₄O₃S 
• 1089279-99-1 3-[3-(2-{[4-(1,4'-bipiperidin-1'-yl)phenyl]amino}-4-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-N-(2,6-difluorophenyl)benzamide 

Relevant academic research and scientific papers

TRICYCLIC INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R3 and R4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors

2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.

Diaminothiazoles

Novel diaminothiazoles of formula (I): [image] are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.

Benzodiazepines as potent and selective bradykinin B1 antagonists

Antagonism of the bradykinin B1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation. Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B1 receptor (Ki = 0.59 nM) and high selectivity against the bradykinin B2 receptor (Ki > 10 nM). In vivo efficacy, comparable to morphine, was demonstrated for lead compounds in a rodent hyperalgesia model.